Why Fed Yield Curve Control Is Price Fixing: Jim Bianco
Jim Bianco, Founder of Bianco Research, on why markets are more hope than reality. Nathan Sheets, Chief Economist for PGIM Fixed Income, on why he's cautiously optimistic the U.S will avoid long-term ...
29 Touko 202021min
Forty Percent of Bars In U.S. May Not Make It: Ritholtz
Barry Ritholtz, Founder of Ritholtz Wealth Management, Bloomberg Opinion columnist, and Host of Masters of Business, discusses the grim future for the U.S. bar scene. Cass Sunstein, Bloomberg Opinion ...
28 Touko 202028min
Twitter Faces Slippery Slope With Fact-Checking: SocialFlow CEO
Jim Anderson, CEO of SocialFlow, on Trump threatening to shut down Twitter and social media after receiving a fact-checking label. Robert Kelchen, Associate Professor of Higher Education at Seton Hall...
27 Touko 202029min
Why Online Education Should Come With An Online Price
Cathy O'Neil, mathematician and Bloomberg Opinion columnist, discusses her column, "Covid-19 Will Make Colleges Prove Their Worth." Michael Hirson, Practice Head, China and Northeast Asia, Eurasia Gro...
26 Touko 202031min
Why Lockdowns Haven’t Proved They’re Worth the Havoc
Joe Nocera, Bloomberg Opinion columnist, discusses his column: Lockdowns Haven’t Proved They’re Worth the Havoc. Twenty co-founder Jared Allgood, discusses Healthy Together, the contact tracing app de...
22 Touko 202029min
China Stock Delisting Threat Is All Bark, No Bite: KraneShares CIO
Brendan Ahern, Chief Investment Officer at KraneShares, on Trump ramping up blame on China and Xi, and the GOP Senate voting to delist China stocks. Donny Dorling, Professor of Geography at Oxford and...
21 Touko 202029min
Now Is The Time To Disrupt Your Business Model: Travelocity Founder
Terry Jones, founder of Travelocity and co-founder of Kayak.com, to discuss why now is a good time for company leaders to innovate their business plans. RJ Gallo, Senior Portfolio Manager: Fixed Incom...
20 Touko 202029min
Moderna Vaccine Holds Promise But In Very, VERY Early Days
Max Nisen, Bloomberg Opinion biotech, pharma and health care columnist, discusses why it's still early days for Moderna's virus vaccine. Lisa Knee, co-leader for the national real estate practice at E...
18 Touko 202026min
